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ABSTRACT  
Introduction: Pegvaliase is a recombinant Anabaena variabilis phenylalanine ammonia 
lyase (PAL) enzyme under investigation for treatment of adult phenylketonuria (PKU). 
This manuscript describes results of a randomized discontinuation trial (RDT) designed 
to evaluate the effects of pegvaliase treatment on blood phenylalanine (Phe) and 
neuropsychiatric outcomes in adults with PKU.  
 
Methods: PRISM-2 is a 4-part, Phase 3 study that enrolled adults with PKU receiving 
pegvaliase treatment (initiated in a prior Phase 2 or Phase 3 study). The RDT, Part 2 of 
PRISM-2, was an 8-week trial that evaluated change in blood Phe concentrations, 
neuropsychiatric and neurocognitive measures, and safety outcomes in PRISM-2 
participants who had achieved at least a 20% blood Phe reduction from pre-treatment 
baseline with pegvaliase treatment. Participants were randomized 2:1 to either continue 
pegvaliase (20 mg/day or 40 mg/day) or switch to matching placebo.  
 
Results: The pooled pegvaliase group enrolled 66 participants and each placebo group 
enrolled 14 participants. The primary endpoint of change in blood Phe concentration 
from RDT entry to RDT Week 8 was met with clinically meaningful and statistically 
significant differences between the pegvaliase and placebo groups. Mean (SD) blood 
Phe at the beginning of the RDT when all participants were receiving pegvaliase was 
563.9 (504.6) µM in the group assigned to the 20 mg/day placebo group (n=14), 508.2 
(363.7) µM in those assigned to the 40 mg/day placebo group (n=14), and 503.9 (520.3) 
µM in those assigned to continue pegvaliase treatment (n=58). At Week 8 of the RDT, 
the least squares mean change (95% confidence interval) in blood Phe was 949.8 µmol/L 
(760.4 to 1139.1) for the 20 mg/day placebo group and 664.8 µmol/L (465.5 to 864.1) 
for the 40 mg/day placebo group in comparison to 26.5 µmol/L (-68.3 to 121.3) for the 
pooled (20 mg/day and 40 mg/day) pegvaliase group (P<0.0001 for pooled pegvaliase 
group vs each placebo group). Adverse events (AEs) were usually lower in the pooled 
placebo group when compared to the pooled pegvaliase group. The most common AEs 
for the pooled pegvaliase and pooled placebo groups were arthralgia (13.6% and 10.3%, 
respectively), headache (12.1% and 24.1%), anxiety (10.6% and 6.9%), fatigue (10.6% 
and 10.3%), and upper respiratory tract infection (1.5% and 17.2%). . 
 
Conclusion: Mean blood Phe reduction was sustained in the pegvaliase group, while 
placebo groups had mean blood Phe concentration increase towards pre-treatment 
baseline levels. Results from this study confirmed the efficacy of pegvaliase in 
maintaining reduced blood Phe concentrations with a manageable safety profile for 
most participants.  
 
Keywords: phenylketonuria, PKU, recombinant Anabaena variabilis PEGylated 
phenylalanine ammonia lyase, pegvaliase 
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1. INTRODUCTION  
Phenylketonuria (PKU; OMIM 261600), an autosomal recessive disorder caused by a 
deficiency in phenylalanine hydroxylase (PAH) enzyme activity, results in an 
accumulation of phenylalanine (Phe) in the blood and brain [1, 2]. Elevated blood Phe 
concentration can cause neurologic, cognitive, developmental, psychiatric, and 
behavioral complications that decrease quality of life [3-5].  
The lifelong goal of PKU treatment is to reduce and maintain blood Phe concentration in 
the range of 120 μmol/L to 360 μmol/L, as recommended by the American College of 
Medical Genetics and Genomics (ACMG) guidelines [2]. Under the guidance of metabolic 
specialists, individuals with PKU are counseled to severely restrict consumption of 
dietary Phe, an essential amino acid present in protein foods, and supplement their 
diets with low-Phe or Phe-free amino acid–fortified medical foods and special low-
protein modified foods [2]. A pharmacologic therapy, sapropterin dihydrochloride 
(sapropterin, KUVAN®, BioMarin Pharmaceutical Inc., Novato, CA), a synthetic form of 
tetrahydrobiopterin, a cofactor for PAH, is also available and indicated for use in 
conjunction with dietary Phe restriction [2, 6].  
Several studies demonstrate that many adults with PKU have elevated blood Phe 
concentrations, indicating that blood Phe control for this population is a significant 
challenge and current treatment strategies are not efficacious for all patients [7-10]. An 
estimated 88% of adults with PKU are unable to adhere to Phe-restriction long term, 
and even in those reporting adherence, blood Phe concentrations above recommended 
ranges commonly occur [4, 10-13]. Sapropterin is currently the only pharmacologic 
agent approved to treat adults with PKU, though it is only effective in patients with 
residual PAH activity; in clinical trials, only 20%-56% of patients with PKU responded to 
sapropterin, as measured by a reduction in blood Phe concentration [2, 6, 14, 15]. There 
remains a significant unmet need for new treatments to help patients achieve guideline-
recommended Phe levels and to optimize long-term patient outcomes [2]. 
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Pegvaliase, produced through PEGylation of recombinant Anabaena variabilis 
phenylalanine ammonia lyase (PAL), is an investigational enzyme substitution therapy 
designed to reduce blood Phe concentration in adults with PKU [16]. The PAL enzyme 
converts Phe to ammonia and trans-cinnamic acid, which are metabolized by the liver 
and excreted in the urine. The addition of polyethylene glycol (PEG) decreases 
immunogenicity and improves drug stability [16, 17]. A Phase 1 clinical study 
demonstrated a single dose of pegvaliase treatment reduced blood Phe concentrations 
[17]. Phase 2 clinical studies of pegvaliase demonstrated that treatment leads to 
meaningful and sustained reductions in blood Phe concentrations [18-20]. 
Thomas et al. recently reported on the overall Phase 3 clinical program for pegvaliase, 
which consisted of two studies, PRISM-1 and PRISM-2 [21]. The findings of the pivotal 
portion of PRISM-2, the randomized discontinuation trial, are reported here 
(NCT01889862).  
The primary aim of the RDT was to evaluate blood Phe concentrations in participants 
who continued receiving a stable dose of pegvaliase compared to participants who were 
administered placebo treatment. 
2. METHODS  
The RDT was an 8-week, randomized, double-blind, placebo-controlled trial in adults 
with PKU (Supplementary Figure 1). The primary objective of the RDT was to determine 
change in blood Phe concentration as treatment was withdrawn in the placebo-treated 
groups compared to the pegvaliase-treated group; the secondary objectives were to 
compare the change in inattention and mood symptoms, and safety; and an exploratory 
substudy had the objective to compare change in executive function between the 
groups.  
Consistent dietary intake of protein and Phe reported at baseline were to be maintained 
throughout the study. Participants recorded all dietary protein intake from medical food 
and natural food for 3 consecutive days prior to each clinic visit in diet diaries, which 
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were analyzed by dietitians using MetabolicPro® (Genetic Metabolic Dietitians 
International, Decatur, Georgia, USA). All individuals consented to participate in the 
study, which was conducted in accordance with the Declaration of Helsinki. 
2.2 RDT Participants 
The RDT enrolled adults aged ≥18 years with PKU receiving 20 mg/day or 40 mg/day 
pegvaliase in Part 1 of PRISM-2. Because hypersensitivity adverse events associated with 
initiating pegvaliase are more common in the first 6 months of treatment and could lead 
to unblinding, the RDT enrolled participants who were already receiving treatment with 
pegvaliase. For participants receiving neuropsychiatric medications, the dose must have 
been stable. All participants must have been willing and able to maintain stable protein 
intake.  
2.3 RDT Randomization   
In the RDT, participants were randomized 2:1 by an interactive web-response system to 
continue their current dose of pegvaliase (20 mg/day or 40 mg/day) or to receive 
matching placebo (20 mg/day or 40 mg/day of Dextran 40®), which contained 22% 
Dextran. Investigators, study staff, participants, and the sponsor were blinded to the 
RDT study drug assignment. 
Randomization was stratified by blood Phe (≤600 µmol/L or >600 µmol/L) using the last 
2 consecutive measurements in Part 1 and Attention Deficit Hyperactivity Disorder 
Rating Scale IV (ADHD RS-IV) inattention (IA) subscale score (≤12 or >12 or missing) 
using the treatment-naïve baseline measurements.  
2.4 RDT Study Drug Administration 
Study product (pegvaliase or placebo) in the RDT was self-administered subcutaneously 
every day for 8 weeks, with rotation of injection sites between doses (ie, upper arm, 
thigh, buttocks, or abdomen) and with at least 1 inch separation between injection sites, 
in the cases of multiple injections (for example, two 20 mg injections given for a 40 mg 
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dose). The date, time, volume, and injection location of each dose of pegvaliase was 
recorded in a workbook that was collected at scheduled clinic visits. The RDT study drug 
compliance rate was calculated for the pegvaliase groups as the total amount of study 
drug taken divided by the planned dose and for the placebo groups as the number of 
days dosed divided by the duration of RDT. 
2.5 Mitigation of Hypersensitivity Adverse Events  
Participants were trained to recognize and respond to potential hypersensitivity adverse 
events (HAEs) and were given epinephrine injectors for use in the case of an acute 
systemic hypersensitivity event, including potential events of anaphylaxis. Investigators 
used clinical judgment to decide if a participant should have an observer present during 
study drug administration or use premedication prior to each dose of study drug with a 
histamine H1 antagonist, H2 antagonist, and, if tolerated, an antipyretic.  
2.6 Assessments  
Assessments in the clinic were performed on Days 1, 28 (Week 4), and 56 (Week 8) of 
the RDT. Efficacy and safety endpoints were compared between those who continued 
pegvaliase and those who switched to placebo.  
The primary efficacy endpoint was change in blood Phe concentration. A secondary 
efficacy endpoint was the change in Attention Deficit Hyperactivity Disorder Rating Scale 
IV, inattention (ADHD RS-IV IA) subscale score for participants with a baseline ADHD RS-
IV IA subscale score >9. Additional secondary efficacy endpoints for the efficacy 
population were changes in ADHD RS-IV IA subscale score, Profile of Mood States 
(POMS) score, PKU-specific Profile of Mood States (PKU-POMS) score, and PKU-POMS 
confusion subscale score. 
Neuropsychiatric assessments for inattention and mood were administered by 
experienced test raters trained on each instrument, previously validated for use in PKU 
[22, 23]. The ADHD RS-IV instrument was administered by investigators and POMS was 
self-administered by study participants. The IA subscale score of the ADHD RS-IV is 
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considered more relevant compared to the hyperactivity subscale of the ADHD RS-IV, as 
inattention symptoms are more prevalent in adults with PKU [23]. The IA subscale score 
ranges from 0 to 27, with higher scores indicating a greater degree of impairment and a 
score >9 indicating the presence of inattention symptoms [23]. The POMS instrument 
consists of a 65-item questionnaire rated using a 5-point Likert scale, and the sum of the 
scores is reported; scores range from -32 to 200, with higher scores indicating greater 
mood symptoms [22]. 
The PKU-POMS includes a subset of the items in the POMS and was developed for the 
PRISM studies to specifically assess transient and variable mood states relevant to PKU 
[22]. It consists of a 20-item questionnaire and is rated using the same 5-point Likert 
scale used in the POMS, with a possible score range of -12 to 58. The confusion subscale 
scores, a 3-item subset questionnaire of the PKU-POMS, are also reported; scores range 
from 0 to 11 in this domain. PKU-POMS and the confusion subscale scores were derived 
from POMS results. 
Additional exploratory neuropsychiatric assessments to evaluate executive function 
were performed in an exploratory sub study (NCT02468570) of RDT participants using 3 
pre-defined tasks from the Cambridge Neuropsychological Test Automated Battery 
(CANTAB) considered relevant for PKU [24]. CANTAB is a computerized and validated set 
of performance-based tasks designed for neuropsychological research that have 
demonstrated sensitivity in detecting executive function impairments [24]. Endpoints 
studied were stop signal task (SST) reaction time, rapid visual processing (RVP) mean 
response latency, and spatial working memory (SWM), with lower scores representing a 
better result [24]. Major executive function domains that were assessed by these 
endpoints include inhibitory control and cognitive flexibility (SST task), sustained 
attention (RVP task), and visuospatial working memory (SWM task).  
Participants were evaluated for safety by assessing vital signs, physical examination, 
adverse events (AEs), and clinical laboratory tests (chemistry, hematology, and 
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urinalysis). Safety endpoints were assessed by examining the incidence, exposure 
adjusted- AE rate, and severity grade for all AEs reported during the study period.  
AEs were coded by preferred term in accordance with the Medical Dictionary for 
Regulatory Activities (MedDRA, version 18.0 [25]). Additional AEs of interest for 
assessments included acute systemic hypersensitivity events, hypersensitivity adverse 
events, injection-site reaction, injection-site skin reaction lasting ≥14 days, generalized 
skin reaction lasting ≥14 days, and arthralgia. 
HAEs were identified using a modified version of the hypersensitivity standardized 
MedDRA query (SMQ) that included preferred terms of arthralgia, arthritis, eye 
inflammation, eye irritation, eye pain, joint stiffness, joint swelling, pyrexia, vision 
blurred and polyarthritis, and the broad algorithmic anaphylactic reaction SMQ.  
Potential acute systemic hypersensitivity events were identified using the 
hypersensitivity SMQ, the anaphylactic reaction SMQ, and MedDRA preferred terms to 
identify all AEs that could potentially be component manifestations of acute systemic 
hypersensitivity events as well as all AEs reported as anaphylactic reactions by preferred 
term. All potential episodes of acute systemic hypersensitivity events were reviewed by 
an allergist/immunologist independent of the clinical site and sponsor to identify events 
consistent with clinical criteria of anaphylaxis defined by the National Institute of Allergy 
and Infectious Diseases/Food Allergy and Anaphylaxis Network (NIAID/FAAN [26]) and 
Brown’s severe criteria [27] (ie, hypoxia, hypotension, or neurologic compromise). 
Injection-site reactions were identified using the MedDRA high level term of injection-
site reaction. Injection-site skin reactions were identified using a specified list of 
MedDRA preferred terms with a reported duration of ≥14 days. Generalized skin 
reactions were identified using a specified list of MedDRA preferred terms and any 
events identified by the MedDRA broad vasculitis SMQ, with a reported duration lasting 
≥14 days. 
2.7 Statistical Analysis  
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Descriptive summaries of continuous variables included number of participants (n), the 
mean, standard deviation (SD), median, minimum, maximum, and 95% confidence 
interval (CI; as appropriate) for the mean. Descriptive summaries of categorical variables 
included number of participants, frequency, and percent. The treatment-naïve baseline 
was defined as the value prior to the first dose of pegvaliase administered in any clinical 
study (ie, pegvaliase-naïve baseline). The RDT entry value for assessments was defined 
as the last available measurement prior to first administration of study drug in the RDT.  
Analyses of the efficacy endpoints were performed using the modified intent-to-treat 
(mITT) population, which consisted of participants that had maintained their pegvaliase 
dose (determined per randomization in PRISM-1 or per randomization upon enrolling in 
Part 1) of 20 mg/day or 40 mg/day in Part 1 of PRISM-2 and that had a blood Phe 
reduction of ≥20% (from the mean of 2 consecutive blood Phe assessments) from 
treatment-naïve baseline at the time of RDT entry. A ≥20% reduction in blood Phe was 
considered a first signal of pharmacologic effect, and used to determine a population 
with which the effects of treatment withdrawal for placebo-treated subjects could be 
observed. In addition, a subgroup analysis was performed for those participants who 
scored >9 on the ADHD RS-IV IA subscale at baseline. For safety analyses, all participants 
who received any study drug in the RDT were included.  
The efficacy endpoint analyses were performed for the change from RDT entry to Week 
8 using mixed model repeated measures (MMRM) method with treatment group (ie, 
pegvaliase, placebo), visit, and treatment-by-visit interaction as factors for adjusting for 
RDT entry blood Phe.  
As RDTs can be affected by carryover effects of prior treatment, the difference in the 
potential carryover effect between the 2 placebo groups was tested (referred to 
hereafter as poolability). The change in blood Phe concentration from RDT entry to 
Week 8 was compared between the 20 mg/day placebo group vs the 40 mg/day placebo 
group using the MMRM method. The 20 mg/day and 40 mg/day placebo groups were 
not deemed poolable (ie, P value was ≤0.1), therefore the comparison for the primary 
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outcome was MMRM analysis between the pooled pegvaliase group vs the 20 mg/day 
placebo group and between the pooled pegvaliase group vs the 40 mg/day placebo 
group. Based on the RDT study design, the pegvaliase-treated groups remained on their 
stable pegvaliase dose throughout the 8 weeks of the RDT. The data for the pegvaliase 
groups were pooled because no change on blood Phe concentration was expected at 
Week 8 of the RDT. 
Statistical tests were 2-sided at the 0.05 significance level, and all CI were 2-sided, 95%. 
Enrollment target was 72 participants to provide 97% power to detect a statistically 
significant difference in the primary endpoint. For analysis of the primary efficacy 
endpoint in RDT, the Hochberg procedure was used for multiplicity adjustment [28]. 
Between the primary and secondary efficacy endpoints and within the secondary 
efficacy endpoints in RDT, the sequential hypothesis testing procedure was used for 
multiplicity adjustment. 
For the safety analyses, data on the incidence, exposure-adjusted event rate, Common 
Terminology Criteria for Adverse Events (CTCAE) severity grade (mild, moderate, severe, 
life-threatening, death) [29], and relationship to pegvaliase of all treatment-emergent 
AEs were reported. Safety was analyzed according to the study drug assignment. 
For the endpoints in the CANTAB substudy, the change from RDT entry to Week 8 was 
compared for the pooled pegvaliase and pooled placebo groups with an analysis of 
covariance (ANCOVA) model using treatment group, RDT entry blood Phe concentration 
and efficacy measure as factors. Cohen’s d method was used for measuring the effect 
size of CANTAB domains for difference between pooled pegvaliase and pooled placebo 
groups, calculated as the difference between means of two treatment groups divided by 
a pooled standard deviation [30]. 
 
3. RESULTS  
3.1 Participant Disposition    
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A total of 86 participants enrolled in the RDT and met eligibility criteria for the efficacy 
analyses. This included 29 participants in each active treatment group (20 mg/day or 
40 mg/day pegvaliase) and 14 participants in each matching placebo group (20 mg/day 
or 40 mg/day placebo). There were 9 additional participants that enrolled in the RDT 
and were randomized to a treatment arm, but as they did not meet criteria for the 
efficacy analyses, these 9 participants are only included in the safety analyses.  
 
3.2 Participant Characteristics  
Participant characteristics are presented in Table 1. Mean blood Phe at RDT entry was 
503.9 µmol/L in the pooled active group and 536.1 µmol/L in the pooled placebo group. 
A total of 5 participants were following a Phe-restricted diet, defined as having >75% of 
their total protein intake from medical food. 
 
 
 
Table 1. Participant Characteristics at RDT Entry (mITT, N=86)    
 
     Pooled Active 
(N=58) 
Pooled Placebo 
(N=28) 
Age at enrollment,   
Mean (SD), years 30.6 (8.4) 31.2 (10.4) 
Min, Max, years 18, 51 19, 51 
Sex, n   
Female 31 (53.4%) 12 (42.9%) 
Race, n   
White 58 (100.0%) 27 (96.4%) 
Body mass index, kg/m2   N=27 
Mean (SD) 28.3 (6.6) 29.9 (7.0) 
Min, Max 17.3, 48.2 19.9, 44.4 
Blood Phe, µmol/L   
Mean (SD) 503.9 (520.3) 536.1 (432.5) 
Min, Max 0, 1721.0 0, 1318.0 
kg, kilogram; Max, maximum; Min, minimum; Phe, phenylalanine; SD, standard 
deviation. Sample size indicated if data was not available for all subjects. 
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3.3 Treatment Compliance 
The mean (SD) treatment drug compliance rate during the RDT for participants receiving 
20 mg/day and 40 mg/day of pegvaliase was 95.9% (9.17%) and 96.7% (4.94%), 
respectively, of the total prescribed dose. The rate in participants receiving 20 mg/day 
or 40 mg/day of placebo was 98.3% (3.32%) and 96.8% (5.32%), respectively. 
 
3.4 Efficacy 
3.4.1 Blood Phe  
From RDT entry to Week 8, mean blood Phe concentration for participants in the 
pegvaliase treatment group was stable, while participants who were switched to 
placebo showed mean blood Phe increases. The primary endpoint of the RDT was met 
with a least squares (LS) mean change (95% CI) from RDT entry to Week 8 of 949.8 
µmol/L (760.4 to 1139.1) for the 20 mg/day placebo group and 664.8 µmol/L (465.5 to 
864.1) for the 40 mg/day placebo group in comparison to 26.5 µmol/L (-68.3 to 121.3) 
for the pooled (20 mg/day and 40 mg/day) pegvaliase group (P<0.0001 for pooled 
pegvaliase group vs each placebo group)(Figure 1). Overall dietary protein intake did not 
change during RDT and analyses adjusting for dietary protein intake suggest it did not 
appreciably affect primary study results. 
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Figure 1. Blood Phe concentration (mITT, N=86). Treatment-naïve baseline was the 
blood Phe value prior to initiating pegvaliase treatment. mITT, modified intent-to-treat 
population; SE, standard error.
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 16 
3.4.2 Neuropsychiatric measures 
 In participants with an ADHD RS-IV IA subscale treatment-naïve score >9, the LS mean changes 
(95%) between the pooled pegvaliase group and the 20 mg/day or 40 mg/day placebo groups 
were 4.7 (-0.19, 9.5; P=0.06) and 2.8 (-2.0, 7.5; P=0.24), respectively, from start of RDT to RDT 
Week 8. For all participants in the efficacy population, the differences in LS mean change (95% 
CI) between the pooled pegvaliase group with the 20 mg/day or 40 mg/day placebo groups 
were 0.5 (-2.1, 3.1; P=0.70) and 1.6 (-1.2, 4.5; P=0.25), respectively. In the analysis of the 
secondary endpoints for neuropsychiatric and mood changes between RDT entry and Week 8, 
there were no significant differences observed between treatment groups (Table S1). 
CANTAB testing results in 9 participants (6 in the pooled pegvaliase group, 3 in the pooled 
placebo group) who additionally participated in this substudy numerically favored pegvaliase 
treatment for all exploratory endpoints. Participants in the pooled pegvaliase group had an 
improvement in sustained attention, measured by RVP mean response latency at Week 8, 
compared with a worsening in the pooled placebo group. The pooled pegvaliase group also 
demonstrated improved visuospatial working memory with a decrease in the number of errors 
made on the SWM, compared with an increase in errors by the placebo group. The pooled 
placebo group had an increased score (greater worsening) in the SST task, measuring inhibitory 
control and cognitive flexibility, as compared to the pooled pegvaliase group (Table S2).  
 
3.5 Safety 
A total of 83.3% and 93.1% of participants in the pooled pegvaliase and pooled placebo groups, 
respectively, reported AEs during the RDT. In the pooled pegvaliase and placebo groups, the 
most commonly reported AEs (by preferred term) were arthralgia, headache, anxiety, fatigue, 
and upper respiratory track infection. AEs with a ≥10% incidence difference between the 
pooled pegvaliase and placebo groups included headache and upper respiratory tract infection. 
(Table 2).  
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 17 
Participants in the pooled pegvaliase and placebo groups reported HAEs (39.4% and 13.8%, 
respectively), generalized skin reactions (10.6% and 0%, respectively) and injection-site skin 
reactions lasting ≥14 days (7.6% and 3.4%, respectively; Table 3).  
The majority of participants experienced an AE that was mild or moderate in severity (53/66 
[80.3%] in the pooled pegvaliase group; 27/29 [93.1%] in the pooled placebo group) and 97.5% 
of AEs did not lead to dose interruption or reduction. There were 2 serious AEs (SAEs), agitation 
and depression (n=1 each) in the 40 mg/day pegvaliase group, both of which resolved and 
participants continued study drug administration. A single SAE occurred in the 20 mg/day 
placebo group of increased blood creatine phosphokinase that resolved. No participant 
discontinued the study drug or withdrew from the trial in RDT due to an AE (Table 3). No acute 
systemic hypersensitivity events including potential events of anaphylaxis were reported during 
the RDT. 
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Table 2. Adverse Events in RDT by Preferred Term With ≥10% Incidence Rate, Reported as the 
Percentage of Participants (safety population, N=95) 
 Pooled Pegvaliase 
(N=66) 
Pooled Placebo 
(N=29) 
Any AE, % (n) 83.3% (55) 93.1% (27) 
Arthralgia 13.6% (9) 10.3% (3) 
Headache 12.1% (8) 24.1% (7) 
Anxiety 10.6% (7) 6.9% (2) 
Fatigue 10.6% (7) 10.3% (3) 
Upper respiratory tract infection 1.5% (1) 17.2% (5) 
Injection site brusing 4.5% (3) 10.3% (3) 
Alopecia 3.0% (2) 10.3% (3) 
Irritability 3.0% (2) 10.3% (3) 
Blood creatinine phosphokinase 
increased 
1.5% (1) 10.3% (3) 
Nasal congestion 1.5% (1) 10.3% (3) 
AE, adverse event; RDT, randomized discontinuation trial. 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
 19 
Table 3. Overview of Adverse Events in RDT, Reported as Event Rate per Person-Year and Total 
Number of Events (safety population, N=95) (Total Events) 
 
Pooled Pegvaliase 
(N=66) 
Pooled Placebo 
(N=29) 
Total treatment exposure, person-years 9.8 4.4 
Event rate, per person-year (total number of 
events) 
42.7 (420) 29.1 (127) 
AEs 83.3 (55) 93.1 (27) 
AEs assessed by the investigator as drug related 66.7 (44) 55.2 (16) 
AEs causing dose interruption or reduction 1.5 (1) 3.4 (1) 
AEs causing study drug discontinuation 0 0 
AEs causing study discontinuation 0 0 
SAEs 3.0 (2) 3.4 (1) 
SAEs assessed by the investigator as drug 
related 
3.0 (2) 0 
SAEs causing study drug discontinuation 0 0 
SAEs causing study discontinuation 0 0 
Acute systemic hypersensitivity event of 
anaphylaxis 
0 0 
Hypsersensitivity adverse event 39.4 (26) 13.8 (4) 
Generalized skin reaction ≥14 days 10.6 (7) 0 
Injection-site skin reaction ≥14 days 7.6 (5) 3.4 (1) 
Arthralgia 13.6 (9) 10.3 (3) 
Injection-site reaction 24.2 (16) 24.1 (7) 
AE, adverse event; RDT, randomized discontinuation trial; SAE, serious adverse event. Event 
rate was calculated as total number of events divided by person-years of exposure. 
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4. DISCUSSION  
The results from the 8-week pivotal, placebo-controlled RDT show significant and clinically 
meaningful changes in blood Phe concentration with pegvaliase treatment in adults with PKU. A 
change in blood Phe concentration was demonstrated with a signficant difference between 
participants who continued pegvaliase and those who switched to matched placebo (P<0.0001); 
mean blood Phe levels in the pegvaliase group were maintained, while those of the placebo-
group increased toward treatment-naïve concentrations, meeting the primary outcome analysis 
in the RDT.  
The blood Phe changes demonstrated with pegvaliase treatment from treatment-naïve baseline 
to RDT entry were substantial, with treatment groups achieving a mean blood Phe 
concentration <600 µmol/L by the time of RDT entry (from treatment-naïve baseline values 
>1100 µmol/L). The eligiblity criteria for the efficacy analyses was used to create a trial 
population in which the effects of pegvalise discontinuation could be readily observed. The RDT 
was not designed to measure the maximum effect of pegvaliase on efficacy endpoints, as 
dosing was based on randomization rather than a participant’s response to pegvaliase, and the 
trial duration was relatively short.  
Though the treatment effect on blood Phe associated with pegvaliase treatment withdrawal 
was demonstrated within 8 weeks in the RDT, a deterioration in neuropsychiatric or 
neurocognitive symptoms was not observed, perhaps because the trial duration or tools used 
were not adequate. The study did not require participants to report neuropsychiatric or 
neurocognitive symptoms at baseline, which may have further limited ability to observe a 
difference. The nature of the ADHD RS-IV IA subscale and POMS tools, which largely depend on 
self-reporting of symptoms, used in a population known to have self-awareness issues affected 
by metabolic Phe control, may have further confounded results [31, 32]. Performance-based 
measures, such as the CANTAB, may be more suitable than self-reporting symptom 
instruments. Exploratory results from the RDT suggest that improvements in executive function 
may be associated with pegvaliase treatment and may be observed within a shorter period of 
time; larger studies with performance-based tools are needed to explore the effect of 
treatment on executive function in adults with PKU.  
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Pegvaliase exhibited a manageable safety profile in most subjects in RDT with similar rates of 
AEs between the pooled pegvaliase and pooled placebo groups. Differences in the event rate of 
HAEs, generalized skin reactions lasting >14 days, and injection-site skin reactions lasting >14 
days were observed with values higher in the pooled pegvaliase group than in the pooled 
placebo group. Overall most participants had events limited to mild or moderate severity and 
did not require dose changes or reductions in the RDT. This report of the RDT is of a selected 
proportion of patients participating in the randomized double-blind portion of the PRISM 
studies during a relatively short exposure period. More information applicable to pegvaliase 
treatment for chronic use has been reported by Thomas et al.  
Suboptimal outcomes are reported in adults with PKU, often associated with the burden of life-
long Phe-restriction or inadequate efficacy of oral treatments to lower blood Phe. Pegvaliase is 
an investigational agent that may provide a daily injectable therapy for adults with PKU. 
Pegvaliase has a different mode of action than currently available PKU treatments and may 
potentially provide a pharmacological option for all adults with PKU, particularly those that 
have not demonstrated an adequate response to sapropterin or dietary approaches. The 
potential efficacy of pegvaliase to lower blood Phe to normal, unaffected population blood Phe 
levels (60-120 µmol/L) may also provide significant benefit, though more studies are needed. As 
with all therapies, risks and benefits of a treatment need to be considered by clinicians in 
determining the appropriate treatment approach for their patient.  
 
5. CONCLUSIONS 
A statistically significant difference in blood Phe concentration change in participants receiving 
pegvaliase compared to placebo treatment was observed, confirming the blood Phe efficacy of 
pegvaliase.   
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